Use of Hyaluronic Acid Gel in the Management of Paralytic Lagophthalmos: The Hyaluronic Acid Gel 'Gold Weight'
| Autor: | Mehryar Taban, Angelo Tsirbas, Robert A. Goldberg, Alan Lowinger, Norman Shorr, Ronald Mancini, Raymond S. Douglas, Tanuj Nakra |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Lagophthalmos Facial Paralysis Ecchymosis chemistry.chemical_compound Hyaluronidase Hyaluronic acid medicine Humans Aponeurosis Corneal reflex Hyaluronic Acid Aged Retrospective Studies Aged 80 and over Blinking business.industry Eyelids General Medicine Middle Aged medicine.disease Facial paralysis Surgery Ophthalmology Treatment Outcome medicine.anatomical_structure chemistry Eyelid Diseases Female Eyelid medicine.symptom business Gels medicine.drug |
| Zdroj: | Ophthalmic Plastic & Reconstructive Surgery. 25:23-26 |
| ISSN: | 0740-9303 |
| DOI: | 10.1097/iop.0b013e318192568d |
| Popis: | Purpose: To evaluate the safety and efficacy of injecting hyaluronic acid gel in the upper eyelid as a nonsurgical alternative in the treatment of paralytic lagophthalmos. Methods: This is a retrospective study of 9 patients (10 eyelids) with paralytic lagophthalmos treated with hyaluronic acid gel in the prelevator aponeurosis region and/or pretarsal region of the paralytic upper eyelid. Pretreatment, posttreatment, and follow-up photographs were digitized, and overall outcomes assessed. Measurements of lagophthalmos were standardized and compared. Slit-lamp examination was used to evaluate the degree of exposure keratopathy. ImageJ was used for photographic analysis. Results: Ten eyelids (9 patients, 7 men; mean age 69.2 years; range, 31‐90 years) with paralytic lagophthalmos were treated with hyaluronic acid gel. The average amount of injected hyaluronic acid gel was 0.9 ml (range, 0.2‐1.2 ml). All patients demonstrated significant improvement in lagophthalmos and exposure keratopathy. The mean improvement in lagophthalmos was 4.8 mm (range, 0.9‐11.9 mm; p 0.001). Of the 5 patients with follow-up, the mean follow-up period was 3.6 months (range, 2‐5 months). Of these, 2 had no change in lagophthalmos (both maintained 0 mm at 5 months), one had a slight decrease in lagophthalmos (4.8‐4.6 mm at 2 months), one had a slight increase in lagophthalmos (0.3‐0.5 mm at 2 months), and one had a more significant increase in lagophthalmos (1.9‐4.3 mm at 4 months). The latter patient underwent a second treatment with further reduction of lagophthalmos to 0.4 mm. Overall, there was a decrease in margin reflex distance from the upper eyelid margin to the corneal light reflex (MRD1) but it was not statistically significant. Complications were minor and included transient ecchymosis, edema, and tenderness at the injection sites. Conclusions: On the basis of these preliminary results, hyaluronic acid gel shows promise as a safe and effective nonsurgical treatment for the management of paralytic lagophthalmos. This treatment may be particularly useful in patients who are poor surgical candidates and/or as a temporizing measure in patients in whom return of facial nerve function is anticipated, given the hyaluronic acid gel’s properties of slow resorption and reversibility with hyaluronidase. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|